BlueCrest Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

BlueCrest Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-22,542	Closed	-$341K	–	957
2015 Q1	$341K	Buy	+22,542	New	+$315K	0.02%	510

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BlueCrest Capital Management's CNCE Position: Q2 2015 in Review

BlueCrest Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2015, closing a stake of 22,542 shares — an estimated $341K sold.

BlueCrest Capital Management first reported a position in CNCE in Q1 2015 and held it in 1 quarter. The position peaked at $341K in Q1 2015. 67 funds tracked by Wall St. Rank hold CNCE as of Q2 2015.

BlueCrest Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
BlueCrest Capital Management sold 22,542 Concert Pharmaceuticals, Inc. shares in Q2 2015, an estimated $341K.
BlueCrest Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
BlueCrest Capital Management's Concert Pharmaceuticals, Inc. position peaked at $341K in Q1 2015.
67 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2015.

Based on BlueCrest Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.